TY - JOUR
T1 - Characterization of the Immune Resistance of Severe Acute Respiratory Syndrome Coronavirus 2 Mu Variant and the Robust Immunity Induced by Mu Infection
AU - Ecuador-COVID19 Consortium
AU - Genotype to Phenotype Japan (G2P-Japan) Consortium
AU - Uriu, Keiya
AU - Cárdenas, Paúl
AU - Muñoz, Erika
AU - Barragan, Veronica
AU - Kosugi, Yusuke
AU - Shirakawa, Kotaro
AU - Takaori-Kondo, Akifumi
AU - Ito, Jumpei
AU - Yamasoba, Daichi
AU - Kimura, Izumi
AU - Suganami, Mai
AU - Oide, Akiko
AU - Yokoyama, Miyabishara
AU - Chiba, Mika
AU - Nakagawa, So
AU - Wu, Jiaqi
AU - Takahashi, Miyoko
AU - Kazuma, Yasuhiro
AU - Nomura, Ryosuke
AU - Horisawa, Yoshihito
AU - Nagata, Kayoko
AU - Yanagida, Yohei
AU - Kawai, Yugo
AU - Tashiro, Yusuke
AU - Kaneda, Atsushi
AU - Nakada, Taka Aki
AU - Seki, Motoaki
AU - Fujiki, Ryoji
AU - Shimada, Tadanaga
AU - Hirahara, Kiyoshi
AU - Yokote, Koutaro
AU - Nakayama, Toshinori
AU - Irie, Takashi
AU - Kawabata, Ryoko
AU - Morizako, Nanami
AU - Fukuhara, Takasuke
AU - Shimizu, Kenta
AU - Tsushima, Kana
AU - Kubo, Haruko
AU - Ikeda, Terumasa
AU - Motozono, Chihiro
AU - Nasser, Hesham
AU - Márquez, Sully
AU - Prado-Vivar, Belén
AU - Becerra-Wong, Mónica
AU - Carvajal, Mateo
AU - Trueba, Gabriel
AU - Rojas-Silva, Patricio
AU - Grunauer, Michelle
AU - Guadalupe, Juan José
N1 - Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.
PY - 2022/10/1
Y1 - 2022/10/1
N2 - Background: We have recently revealed that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Mu variant shows a pronounced resistance to antibodies elicited by natural SARS-CoV-2 infection and vaccination. Methods: However, it remains unclear which mutations determine the resistance of SARS-CoV-2 Mu to antiviral sera. In addition, it is unclear how SARS-CoV-2 Mu infection induces antiviral immunity. Results: In this study, we reveal that the 2 mutations in the SARS-CoV-2 Mu spike protein, YY144-145TSN and E484K, are responsible for the resistance to coronavirus disease 2019 convalescent sera during early 2020 and vaccine sera. Conclusions: It is notable that the convalescent sera of SARS-CoV-2 Mu-infected individuals are broadly antiviral against Mu as well as other SARS-CoV-2 variants of concern and interest.
AB - Background: We have recently revealed that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Mu variant shows a pronounced resistance to antibodies elicited by natural SARS-CoV-2 infection and vaccination. Methods: However, it remains unclear which mutations determine the resistance of SARS-CoV-2 Mu to antiviral sera. In addition, it is unclear how SARS-CoV-2 Mu infection induces antiviral immunity. Results: In this study, we reveal that the 2 mutations in the SARS-CoV-2 Mu spike protein, YY144-145TSN and E484K, are responsible for the resistance to coronavirus disease 2019 convalescent sera during early 2020 and vaccine sera. Conclusions: It is notable that the convalescent sera of SARS-CoV-2 Mu-infected individuals are broadly antiviral against Mu as well as other SARS-CoV-2 variants of concern and interest.
KW - COVID-19
KW - Mu variant
KW - SARS-CoV-2
KW - immune resistance
UR - http://www.scopus.com/inward/record.url?scp=85129088227&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiac053
DO - 10.1093/infdis/jiac053
M3 - Artículo
C2 - 35176774
AN - SCOPUS:85129088227
SN - 0022-1899
VL - 226
SP - 1200
EP - 1203
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 7
ER -
